Literature DB >> 7689552

Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.

J M Culouscou1, G D Plowman, G W Carlton, J M Green, M Shoyab.   

Abstract

We recently reported the molecular cloning of HER4/p180erbB4, a new member of the epidermal growth factor receptor family, as well as its activation by a partially purified ligand (Plowman, G. D., Culouscou, J.-M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1746-1750). In this report we describe the purification to homogeneity of a 45-kDa protein (p45) that induces the differentiation of MDA-MB-453 human breast cancer cells and stimulates the tyrosine phosphorylation of p180erbB4, the HER4-encoded protein. Hydrophobic interaction, ion-exchange, heparin, and size exclusion chromatographies were used to purify this p180erbB4 activator to homogeneity. N-terminal amino acid sequencing suggests that p45 is related to heregulin, a recently reported ligand for p185erbB2. Binding and cross-linking experiments demonstrated that p45 specifically binds to cells expressing recombinant p180erbB4 and not cells expressing recombinant p185erbB2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689552

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Authors:  Samuel Bouyain; Patti A Longo; Shiqing Li; Kathryn M Ferguson; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

3.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

4.  Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

Authors:  J P Vaughn; J D Iglehart; S Demirdji; P Davis; L E Babiss; M H Caruthers; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

5.  Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

Authors:  C I Sartor; H Zhou; E Kozlowska; K Guttridge; E Kawata; L Caskey; J Harrelson; N Hynes; S Ethier; B Calvo; H S Earp
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

7.  Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy.

Authors:  S O'Shea; K Johnson; R Clark; M X Sliwkowski; S L Erickson
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

8.  Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.

Authors:  S S Bacus; C R Zelnick; D M Chin; Y Yarden; D B Kaminsky; J Bennington; D Wen; J N Marcus; D L Page
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

Review 9.  The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

Authors:  H Shelton Earp; Benjamin F Calvo; Carolyn I Sartor
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

10.  ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Authors:  R Pinkas-Kramarski; M Shelly; B C Guarino; L M Wang; L Lyass; I Alroy; M Alimandi; A Kuo; J D Moyer; S Lavi; M Eisenstein; B J Ratzkin; R Seger; S S Bacus; J H Pierce; G C Andrews; Y Yarden; M Alamandi
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.